| Typicality: | 0.396 |
| Saliency: | 0.343 |
| toward u.s. legislation | 17 | transitive-object |
| sale → be affected by → regulatory, clinical and guideline developments | 32 |
| negative | neutral | positive |
| 0.333 | 0.641 | 0.025 |
| Raw frequency | 32 |
| Normalized frequency | 0.343 |
| Modifier score | 0.500 |
| Perplexity | 72.991 |